Abstract
Product description
The present Competitive Intelligence Report about Targeted Therapy of
Hepatitis C provides a competitor evaluation in the field of specifically
targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2009.
Purchase of the downloadable pdf report includes a 6-month online access to
the data of the report and any updates since the publication date. Credentials
to access the database will be sent by e-mail and allow online work with the
project data to print or export an individual report.
Most hepatitis C virus (HCV) infected individuals seeking treatment are
chronically infected. Treatment goal is to achieve a sustained virological
response (SVR), which is the absence of serum HCV RNA up to 6 months after
therapy is concluded. To increase efficiency of interferon treatment,
pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with
ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted
in a further increase in treatment efficiency with 54% of HCV infected
patients achieving SVR. The response and rate of SVR is dependent on the
genotype of HCV with only 30% of genotype 1 infected individuals achieving
SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination
therapy. Combination therapy treatment regiments are genotype dependent and
the amount of peg-IFN-α administered is dependent on the type used.
The suboptimal response has led to a shift in the investigational focus for
treatment of HCV toward specifically targeted antiviral therapy for HCV
agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with
frequent side effects and have a negative impact on the patient' s quality of
life. Among the first wave of targeted HCV therapeutics are the NS3a protease
and NS5B RNA polymerase inhibitors with 25 different compounds in clinical
development and further 8 in the IND enabling study phase. Development of HCV
protease inhibitors is slightly ahead of polymerase inhibitors. The first
study combining HCV protease and polymerase inhibitors was successfully
completed.
At least 17 further distinct molecules are in early clinical development and
another five close to enter clinical investigation which have novel mechanisms
of action. Among the targets are cyclophilin inhibitors, NS5A protein
inhibitors, NS4B-RNA binding inhibitors, viral entry and replication
inhibitors. Specific therapeutic vaccines and antibodies are included in those
novel targeted HCV treatment modalities. Other novel mechanism of action
agents are directed against host cell or viral structures.
The report includes a compilation of current active projects in research and
development of molecules specifically directed against novel targets in
hepatitis C. In addition, the report lists company-specific R&D pipelines of
targeted therapeutics in hepatitis C.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About La Merie Business Intelligence
La Merie Business Intelligence provides R&D information to the
biopharmaceutical industry. Our deliverables are a tool for your innovation in
R&D based on selected, relevant and validated information. La Merie Business
Intelligence was founded in 2002 by Dr. Ulrich Martin to provide expert
consulting services to the biopharmaceutical industry. Based on his extensive
experience in the biopharmaceutical industry both as a physician specializing
in pharmacology and as a co-founder and CEO of a product development company,
La Merie Business Intelligence provides R&D information by individual
consultancy, standard Competitive Intelligence reports and by online content
at PipelineReview.com.
| 
View Cart
